IP Library Granted Patent US 7,632,794
Granted Patent B1
US 7,632,794 · App. 12/235,171 · Granted Dec 15, 2009

Lens care solutions comprising alkyldimonium hydroxypropyl alkylglucosides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,632,794
App. No.
12/235,171
Granted
Dec 15, 2009
Kind
B1
Abstract

A contact lens care solution comprising one or more alkyldimonium hydroxypropyl alkylglucosides of general formula I or general formula II wherein R is a straight or branched C 8 -C 24 alkyl; A is —CH 2 CH(OH)CH 2 N + (CH 3 ) 2 R 1 X − , wherein R 1 is a C 8 -C 24 alkyl and X − is a common counteranion, n is an average value from 1 to 6 and m is an average value from 1 to 2. The solution is formulated to clean and disinfect contact lenses or the solution is formulated as a rewet eye drop for use with contact lenses.

Claims (68)

1. A contact lens care solution comprising:

one or more alkyldimonium hydroxypropyl alkylglucosides of general formula I or general formula II,

wherein R is a straight or branched C 8 -C 24 alkyl;

A is —CH 2 CH(OH)CH 2 N + (CH 3 ) 2 R 1 X − , wherein R 1 is a C 8 -C 24 alkyl and X − is a common counteranion, n is an average value from 1 to 6 and m is an average value from 1 to 2;

poly(hexamethylene biguanide) at a concentration from 0.05 ppm to 2 ppm; and

a buffer system to maintain the pH of the composition from 7.2 to 8.5, wherein the composition is formulated to clean and disinfect contact lenses.

2. The lens care solution of claim 1 wherein the alkyldimonium hydroxypropyl alkylglucoside of general formula I is selected from the group consisting of

stearyldimoniumhydroxypropyl laurylglucosides chloride,

stearyldimoniumhydroxypropyl laurylglucosides chloride,

stearyldimoniumhydroxypropyl decylglucosides chloride,

lauryldimoniumhydroxypropyl laurylglucosides chloride,

lauryldimoniumhydroxypropyl decylglucosides chloride and

trimoniumhydroxypropyl cocoglucosides chloride.

3. The lens care solution of claim 1 wherein the alkyldimonium hydroxypropyl alkylglucoside of general formula II is selected from the group consisting of

polystearyldimonium hydroxypropyl laurylglucosides chloride,

polystearyldimonium hydroxypropyl decylglucosides chloride,

polylauryldimonium hydroxypropyl laurylglucosides chloride,

polylauryldimonium hydroxypropyl decylglucosides chloride,

polytrimonium hydroxypropyl laurylglucosides chloride and

polytrimonium hydroxypropyl decylglucosides chloride.

4. The lens care solution of claim 1 wherein the alkyldimonium hydroxypropyl alkylglucoside of general formula I or general formula II is present in the solution from 0.001% to 0.05% by weight.

5. A The lens care solution of claim 1 wherein the one or more alkyldimonium hydroxypropyl alkylglucoside includes stearyldimonium hydroxypropyl laurylglucoside.

6. The lens care solution of claim 1 wherein the one or more alkyldimonium hydroxypropyl alkylglucoside includes stearyldimonium hydroxypropyl decylglucoside.

7. The lens care solution of claim 1 further comprising polyquaternium-1 at a concentration from 1 ppm to 10 ppm.

8. The lens care solution of claim 1 further comprising polyquaternium-1 at a concentration from 1 ppm to 3 ppm.

9. The lens care solution of claim 1 further comprising an amphoteric surfactant of general formula A,

wherein R 1 is R or —(CH 2 ) n —NHC(O)R, wherein R is a C 8 -C 30 alkyl optionally substituted with hydroxyl and n is 2, 3 or 4; R 2 and R 3 are each independently selected from the group consisting of hydrogen and C 1 -C 4 alkyl; R 4 is a C 2 -C 8 alkylene optionally. substituted with hydroxyl; and Y is CO 2 − or SO 3 − .

10. A contact lens care solution comprising:

0.001% to 0.1% by weight of one or more alkyldimonium hydroxypropyl alkylglucosides of general formula I or general formula II,

wherein R is a straight or branched C 8 -C 24 alkyl;

A is —CH 2 CH(OH)CH 2 N + (CH 3 ) 2 R 1 X − , wherein R 1 is a C 8 -C 24 alkyl and X − is a common counteranion, n is an average value from 1 to 6 and m is an average value from 1 to 2;

0.3 to 1.3 ppm poly(hexamethylene biguanide);

an amphoteric surfactant of general formula A,

wherein R 1 is R or —(CH 2 ) n —NHC(O)R, wherein R is a C 8 -C 30 alkyl optionally substituted with hydroxyl and n is 2, 3 or 4; R 2 and R 3 are each independently selected from the group consisting of hydrogen and C 1 -C 4 alkyl; R 4 is a C 2 -C 8 alkylene optionally substituted with hydroxyl; and Y is CO 2 − or SO 3 − ; and

a buffer system to maintain the pH of the composition from 7.2 to 8.5, wherein the composition is formulated to clean and disinfect contact lenses.

11. The lens care solution of claim 10 , wherein the alkyldimonium hydroxypropyl alkylglucoside of general formula II is selected from the group consisting of

polystearyldimonium hydroxypropyl laurylglucosides chloride,

polystearyldimonium hydroxypropyl decylglucosides chloride,

polylauryldimonium hydroxypropyl laurylglucosides chloride,

polylauryldimonium hydroxypropyl decylglucosides chloride,

polytrimonium hydroxypropyl laurylglucosides chloride and

polytrimonium hydroxypropyl decylglucosides chloride.

12. The lens care solution of claim 10 wherein the one or more alkyldimonium hydroxypropyl alkylglucoside includes stearyldimonium hydroxypropyl laurylglucoside or stearyldimonium hydroxypropyl decylglucoside.

13. The lens care solution of claim 10 further comprising a comfort agent selected from the group consisting of propylene glycol, hydroxypropylmethyl cellulose, hydroxylpropyl guar and hyaluronic acid.

14. The lens care solution of claim 13 wherein the comfort agent is hyaluronic acid.

15. The lens care solution of claim 1 wherein the contact lenses are silicone hydrogel contact lenses.

16. A contact lens care solution comprising:

0.001% to 0.1% by weight of one or more alkyldimonium hydroxypropyl alkylglucosides of general formula I or general formula II,

wherein R is a straight or branched C 8 -C 24 alkyl;

A is —CH 2 CH(OH)CH 2 N + (CH 3 ) 2 R 1 X − , wherein R 1 is a C 8 -C 24 alkyl and X − is a common counteranion, n is an average value from 1 to 6 and m is an average value from 1 to 2;

0.5 to 15 ppm of polyquaternium-1; and

a buffer system to maintain the pH of the composition from 7.2 to 8.5, wherein the composition is formulated to clean and disinfect contact lenses.

17. The lens care solution of claim 16 wherein the alkyldimonium hydroxypropyl alkylglucoside of general formula II is selected from the group consisting of

polystearyldimonium hydroxypropyl laurylglucosides chloride,

polystearyldimonium hydroxypropyl decylglucosides chloride,

polylauryldimonium hydroxypropyl laurylglucosides chloride,

polylauryldimonium hydroxypropyl decylglucosides chloride,

polytrimonium hydroxypropyl laurylglucosides chloride and

polytrimonium hydroxypropyl decylglucosides chloride.

18. The lens care solution of claim 16 wherein the one or more alkyldimonium hydroxypropyl alkylglucoside includes stearyldimonium hydroxypropyl laurylglucoside or stearyldimonium hydroxypropyl decylglucoside.

19. A contact lens care solution comprising:

one or more alkyldimonium hydroxypropyl alkylglucosides of general formula I or general formula II,

wherein R is a straight or branched C 8 -C 24 alkyl;

A is —CH 2 CH(OH)CH 2 N + (CH 3 ) 2 R 1 X − , wherein R 1 is a C 8 -C 24 alkyl and X − is a common counteranion, n is an average value from 1 to 6 and m is an average value from 1 to 2; and

a buffer system to maintain the pH of the composition from 7.2 to 8.5, wherein the composition has an osmolality in the range of at least 200 mOsmol/kg to 400 mOsmol/kg and is formulated to clean and disinfect contact lenses.

20. The lens care solution of claim 19 where in the one or more alkyldimonium hydroxypropyl alkylglucoside includes stearyldimonium hydroxypropyl laurylglucoside or stearyldimonium hydroxypropyl decylglucoside.

21. The lens care solution of claim 19 further comprising a comfort agent selected from the group consisting of propylene glycol, hydroxypropylmethyl cellulose, hydroxylpropyl guar and hyaluronic acid.

22. The lens care solution of claim 19 further comprising a cationic antimicrobial component selected from quaternary ammonium compounds and polymers thereof and low and high molecular weight biguanides.

Assignments (15)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Jul 19, 2017
From: BAUSCH & LOMB INCORPORATED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0932 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
RELEASE OF SECURITY INTEREST Recorded Aug 5, 2012
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 028726/0142 →
SECURITY AGREEMENT Recorded Apr 19, 2010
From: WP PRISM, INC.; BAUSCH & LOMB INCORPORATED; B&L CRL INC.; B&L CRL PARTNERS L.P.; B & L DOMESTIC HOLDINGS CORP.; B & L FINANCIAL HOLDINGS CORP.; B&L SPAF INC.; B&L VPLEX HOLDINGS, INC.; BAUSCH & LOMB CHINA, INC.; BAUSCH & LOMB INTERNATIONAL INC.; BAUSCH & LOMB REALTY CORPORATION; BAUSCH & LOMB SOUTH ASIA, INC.; BAUSCH & LOMB TECHNOLOGY CORPORATION; IOLAB CORPORATION; RHC HOLDINGS, INC.; SIGHT SAVERS, INC.; WILMINGTON MANAGMENT CORP.; WILMINGTON PARTNERS L.P.; B&L MINORITY DUTCH HOLDINGS LLC; EYEONICS, INC.
To: CREDIT SUISSE AG, AS ADMINISTRATIVE AGENT
Reel/Frame 024244/0812 →
SECURITY AGREEMENT Recorded Nov 18, 2008
From: BAUSCH & LOMB INCORPORATED; WP PRISM, INC.; B&L CRL INC.; B&L CRL PARTNERS L.P.; B & L DOMESTIC HOLDINGS CORP.; B&L FINANCIAL HOLDINGS CORP.; B&L SPAF INC.; B&L VPLEX HOLDINGS, INC.; BAUSCH & LOMB CHINA, INC.; BAUSCH & LOMB INTERNATIONAL INC.; BAUSCH & LOMB REALTY CORPORATION; BAUSCH & LOMB SOUTH ASIA, INC.; BAUSCH & LOMB TECHNOLOGY CORPORATION; IOLAB CORPORATION; RHC HOLDINGS, INC.; SIGHT SAVERS, INC.; WILMINGTON MANAGEMENT CORP.; WILMINGTON PARTNERS L.P.; B&L MINORITY DUTCH HOLDINGS LLC; EYEONICS, INC.
To: CREDIT SUISSE
Reel/Frame 021849/0244 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2008
From: XIA, ERNING; MILLARD, KIMBERLY; VENKATESH, SRINI
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 021567/0908 →